Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AOB203
- Development stage
- Unknown
- Lead developer
- AOBiome LLC
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal, Topical
01
Overview
AOB203 (also known as B244) is a first-in-class, live biotherapeutic product consisting of a single strain of beneficial Ammonia Oxidizing Bacteria (AOB), specifically *Nitrosomonas eutropha* strain D23. Developed by AOBiome, AOB203 is formulated as an intranasal spray or topical mist. Once administered, the bacteria metabolize naturally occurring ammonia in sweat and secretions to produce nitric oxide (NO) and nitrite, which act as signaling molecules to regulate inflammation and vasodilation. AOB203 is being evaluated in Phase 2 clinical trials for the preventive treatment of episodic migraine and seasonal allergic rhinitis, and is in Phase 3 development for atopic dermatitis and associated pruritus.
- Other names
- Nitrosomonas eutrophaNitrosomonas eutropha D23Nitrosomonas eutropha strain D23
02
Targets
IL-4 (Interleukin 4)IL31 (IL-31)IL-13 (Interleukin-13)IL-5 (Interleukin 5)
Beyond the preview
Go deeper on AOB203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AOB203.